International Journal of Innovative Technologies in Social Science

e-ISSN: 2544-9435

Operating Publisher
SciFormat Publishing Inc.
ISNI: 0000 0005 1449 8214

2734 17 Avenue SW,
Calgary, Alberta, T3E0A7,
Canada
+15878858911
editorial-office@sciformat.ca

ARTICLE TITLE	THE ASPARTAME DILEMMA IN MODERN PUBLIC HEALTH: A COMPREHENSIVE NARRATIVE REVIEW OF CARCINOGENIC POTENTIAL, METABOLIC PERTURBATIONS, AND SOCIO-REGULATORY CHALLENGES
DOI	https://doi.org/10.31435/ijitss.1(49).2026.5167
RECEIVED	25 January 2026
ACCEPTED	17 March 2026
PUBLISHED	26 March 2026
LICENSE	The article is licensed under a **Creative Commons Attribution 4.0 International License.**

© The author(s) 2026.
This article is published as open access under the Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing the author to retain copyright. The CC BY 4.0 License permits the content to be copied, adapted, displayed, distributed, republished, or reused for any purpose, including adaptation and commercial use, as long as proper attribution is provided.

THE ASPARTAME DILEMMA IN MODERN PUBLIC HEALTH: A COMPREHENSIVE NARRATIVE REVIEW OF CARCINOGENIC POTENTIAL, METABOLIC PERTURBATIONS, AND SOCIO-REGULATORY CHALLENGES

Norbert Gromadzki *(Corresponding Author, Email: norbertgromadzkimed@wp.pl)*
Cardinal Stefan Wyszyński University in Warsaw, Warsaw, Poland
ORCID ID: 0009-0007-9954-6132

Maria Kurt
Cardinal Stefan Wyszyński University in Warsaw, Warsaw, Poland
ORCID ID: 0009-0006-6820-4538

Grzegorz Jałoszyński
Cardinal Stefan Wyszyński University in Warsaw, Warsaw, Poland
ORCID ID: 0009-0004-3763-4311

Oliwia Marciniak
Cardinal Stefan Wyszyński University in Warsaw, Warsaw, Poland
ORCID ID: 0009-0008-5282-2539

Sebastian Konecki
Cardinal Stefan Wyszyński University in Warsaw, Warsaw, Poland
ORCID ID: 0009-0006-0152-7914

Natalia Bylak
Cardinal Stefan Wyszyński University in Warsaw, Warsaw, Poland
ORCID ID: 0009-0009-7405-9041

Anna Gwizdek
Independent Researcher, Warsaw, Poland
ORCID ID: 0009-0004-8037-6020

Dawid Szczepański
Independent Researcher, Warsaw, Poland
ORCID ID: 0009-0000-8430-0905

Bruno Makowski
Medical Center HCP, John Paul II Hospital, Poznań, Greater Poland, Poland
ORCID ID: 0009-0007-5806-0822

Marcin Patryk Barbachowski
Cardinal Stefan Wyszyński University in Warsaw, Warsaw, Poland
ORCID ID: 0009-0008-4315-7477

ABSTRACT

Aspartame remains one of the most scrutinized synthetic food additives worldwide. This narrative review provides an integrative analysis of its systemic health impacts, focusing on the 2023 International Agency for Research on Cancer (IARC) classification of aspartame as a Group 2B possible carcinogen and its implications for public health policy. By synthesizing epidemiological evidence from the NutriNet-Santé cohort, contemporary meta-analyses (2021–2026), and mechanistic studies on oxidative stress and gut dysbiosis, this paper evaluates the "aspartame paradox" - the tension between its intended role in caloric reduction and its potential as a metabolic and oncological disruptor. Furthermore, the review examines socio-regulatory challenges in risk communication, analyzing how divergent global guidelines influence consumer behavior and health equity. Ultimately, this review underscores the need for a unified regulatory framework to better inform public health initiatives.

KEYWORDS

Aspartame, Non-Nutritive Sweeteners, Carcinogenesis, Gut Microbiome, Public Health Policy, Oxidative Stress

CITATION

Norbert Gromadzki, Maria Kurt, Grzegorz Jałoszyński, Oliwia Marciniak, Sebastian Konecki, Natalia Bylak, Anna Gwizdek, Dawid Szczepański, Bruno Makowski, Marcin Patryk Barbachowski. (2026) The Aspartame Dilemma in Modern Public Health: A Comprehensive Narrative Review of Carcinogenic Potential, Metabolic Perturbations, and Socio-Regulatory Challenges. *International Journal of Innovative Technologies in Social Science*. 1(49). doi: 10.31435/ijitss.1(49).2026.5167

COPYRIGHT

© The author(s) 2026. This article is published as open access under the **Creative Commons Attribution 4.0 International License (CC BY 4.0)**, allowing the author to retain copyright. The CC BY 4.0 License permits the content to be copied, adapted, displayed, distributed, republished, or reused for any purpose, including adaptation and commercial use, as long as proper attribution is provided.

1. Introduction

Aspartame, a low-calorie dipeptide methyl ester, has been a cornerstone of the global low-calorie food and beverage industry for over four decades. Approved for use in thousands of consumer products - ranging from carbonated beverages to pharmaceutical formulations - it is approximately 200 times sweeter than sucrose. Despite its long-standing approval by regulatory bodies such as the Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA), aspartame has remained at the center of a protracted scientific debate and public scrutiny.

The discourse reached a critical inflection point in 2023 when the International Agency for Research on Cancer (IARC) classified aspartame as "possibly carcinogenic to humans" (Group 2B), citing limited but concerning evidence regarding hepatocellular carcinoma (Riboli et al., 2023). This classification has created a complex public health and regulatory challenge: while the Joint FAO/WHO Expert Committee on Food Additives (JECFA) maintains that the Acceptable Daily Intake (ADI) of 40 mg/kg body weight remains safe, the psychological and behavioral impact on consumers has been profound (More et al., 2024).

The purpose of this review is to bridge the gap between molecular toxicology and public health policy. By analyzing the metabolic pathways of aspartame - specifically its breakdown into aspartic acid, phenylalanine, and methanol - this paper explores the biochemical mechanisms behind its alleged genotoxicity and metabolic interference (Czarnecka et al., 2021). Additionally, this review examines the systemic effects of chronic consumption on the gut microbiome and insulin sensitivity, providing a 2026 update on the safety profile of this ubiquitous sweetener.

2. Methodology

This narrative review is based on a comprehensive search of peer-reviewed literature indexed primarily in the PubMed and PubMed Central (PMC) databases, supplemented by targeted searches of publisher-specific repositories (e.g., MDPI). To capture both foundational context and recent developments - particularly post-IARC classification data - the review prioritized high-impact studies published between 2021 and 2026.

The search strategy utilized specific keywords and search strings, including "aspartame safety," "non-nutritive sweeteners and cancer," "gut microbiome dysbiosis," and "public health risk communication." Following an initial screening process, 14 core studies - comprising randomized controlled trials, large-scale

epidemiological cohorts (e.g., the NutriNet-Santé study), and systematic reviews - were selected as the primary evidence base. Data were qualitatively synthesized and structured to address three thematic pillars:

- oncological and genotoxic risk mechanisms,
- metabolic impacts and the gut-brain axis, and
- socio-regulatory and consumer safety implications.

3. Results

3.1. Metabolic Hydrolysis and the Generation of Reactive Metabolites

The primary concern regarding aspartame's safety stems from its complete hydrolysis in the gastrointestinal tract. Unlike other non-sugar sweeteners (NNS), aspartame is not excreted intact but is broken down into three primary components: phenylalanine (50%), aspartic acid (40%), and methanol (10%) (Czarnecka et al., 2021).

As highlighted by Soffritti et al. (2010), the chronic release of low-dose methanol may trigger cumulative oxidative stress. Once absorbed, methanol is oxidized into formaldehyde and subsequently into formic acid. Modern toxicological assessments suggest that these metabolites can induce the production of reactive oxygen species (ROS), potentially overwhelming cellular antioxidant defenses, such as glutathione levels. This oxidative imbalance serves as a foundational mechanism for genomic instability and protein carbonylation, which may contribute to long-term cellular aging and malignancy (Prantera et al., 2023).

3.2. Oncological Evidence: Deciphering the IARC 2B Classification

The oncological debate is heavily influenced by the NutriNet-Santé cohort findings, which analyzed data from over 102,000 participants. The study reported a statistically significant association between high aspartame intake and increased overall cancer risk, specifically for breast and obesity-related cancers (Debras et al., 2022).

The IARC 2B classification was primarily supported by *limited evidence* in human studies for hepatocellular carcinoma and *limited evidence* in experimental animals (Riboli et al., 2023). However, the divergence between the IARC's focus on hazard identification and the JECFA's focus on risk assessment has led to significant public risk confusion. While JECFA argues that the current ADI is sufficient to protect consumers, independent analyses suggest that the cumulative effect of consuming multiple NNS-containing products may lead to higher-than-expected systemic concentrations of metabolites (Landrigan & Belpoggi, 2023).

To appreciate the weight of the IARC classification, a granular analysis of the NutriNet-Santé cohort (2009–2021) is essential. Unlike previous retrospective studies that relied on participant memory, this study utilized repeated 24-hour dietary records, which were then linked to national health insurance databases to track cancer incidences.

3.2.1. Statistical Adjustments and Confounding Variables

A critical point of discussion in public health is whether consumers of low-calorie products are simply less healthy at baseline. The NutriNet-Santé researchers addressed this by adjusting for an exhaustive list of variables: age, sex, educational level, physical activity, smoking status, BMI, height, and weight gain during follow-up. Furthermore, the statistical models accounted for baseline intakes of energy, alcohol, sodium, saturated fatty acids, and fiber.

Despite these adjustments, the results remained consistent: participants with the highest intake of aspartame had a hazard ratio (*HR*) of 1.15 for overall cancer compared to non-consumers (Debras et al., 2022). This 15% increase is particularly significant in the context of breast cancer and obesity-related malignancies. From a public health perspective, these data raise critical questions regarding informed choice: if the risk is statistically significant even after adjusting for lifestyle, is the current labeling of zero-calorie products sufficient to inform the consumer of potential long-term biological costs?

3.3. Metabolic Perturbations: The Gut-Insulin-Microbiome Axis

A critical expansion in aspartame research concerns its role as a metabolic disruptor rather than a neutral sugar substitute. Emerging evidence suggests that aspartame influences glucose homeostasis through several indirect pathways.

3.3.1. Sweet Taste Receptors and Incretin Dysregulation

Aspartame interacts with T1R2 and T1R3 sweet taste receptors located not only on the tongue but also on gut enteroendocrine L-cells and pancreatic β-cells. Studies indicate that this non-caloric sweetness can trigger a cephalic phase insulin response (CPIR) and disrupt the incretin system, which primarily involves glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) (Suez et al., 2022). When aspartame binds to these receptors in the gut, it triggers a signaling cascade that mimics the presence of glucose. Because no actual glucose enters the bloodstream, the body experiences a metabolic mismatch. Recent data from Suez et al. (2022) and Aronica et al. (2024) suggest that this chronic false signaling can lead to the downregulation of GLP-1 sensitivity, resulting in delayed postprandial insulin responses when caloric sugars are consumed. Furthermore, aspartame-induced dysregulation of GLP-1 can alter gastric emptying, disrupting satiety cues and contributing to compensatory overeating.

3.3.2. Gut Microbiota Dysbiosis and Metabolic Endotoxemia

A significant finding in recent years is the impact of NNS on the intestinal ecosystem. Chronic aspartame consumption can profoundly alter the composition and function of the gut microbiota (Aronica et al., 2024; Suez et al., 2022). Supplementation has been linked to taxonomic shifts, specifically a decrease in beneficial butyrate-producing taxa, such as *Bifidobacterium* and *Lactobacillus*, alongside an increase in bacteria associated with inflammation and glucose intolerance. The interaction between aspartame and the microbiome also produces secondary metabolites, such as short-chain fatty acids (SCFAs), in altered ratios. The resulting reduction in butyrate weakens intestinal barrier integrity, leading to increased intestinal permeability. This allows for the translocation of lipopolysaccharides (LPS) into the portal circulation, triggering metabolic endotoxemia - a state of chronic, low-grade systemic inflammation recognized as a precursor to type 2 diabetes and cardiovascular disease (More et al., 2024).

3.3.3. The Dissociation Paradox and Insulin Resistance

The dissociation between sweet taste and caloric intake may induce metabolic dysregulation. Long-term epidemiological data suggest that high consumers of aspartame often exhibit a higher body mass index (BMI) and increased waist circumference compared to non-users. This phenomenon, often termed the aspartame paradox, suggests that instead of aiding weight loss, the sweetener may contribute to insulin resistance by altering the body's predictive response to sweetness and disrupting homeostatic energy regulation (Landrigan & Belpoggi, 2023; Prantera et al., 2023).

3.4. Neurobehavioral Effects and the Blood-Brain Barrier (BBB)

The impact of aspartame on neurological health is one of the most contentious areas of its safety profile. Unlike other sweeteners that remain largely within the gastrointestinal tract, the metabolites of aspartame - specifically phenylalanine and methanol - have the potential to cross the blood-brain barrier (BBB) and alter neurochemical homeostasis (Czarnecka et al., 2021).

3.4.1. Large Neutral Amino Acid Transporter 1 (LAT1) Competition

Phenylalanine, which constitutes 50% of the aspartame molecule, is a precursor to several essential neurotransmitters. However, an acute or chronic elevation in plasma phenylalanine levels can disrupt the transport of other large neutral amino acids (LNAAs) into the brain. Phenylalanine competes for the LAT1 carrier with tryptophan and tyrosine, which are precursors to serotonin, dopamine, and norepinephrine, respectively (Prantera et al., 2023).

As noted by Czarnecka et al. (2021), high intake of aspartame may lead to a reduction in brain tryptophan levels, subsequently lowering serotonin synthesis. This biochemical shift has been clinically associated with altered mood states, increased irritability, and, in some susceptible individuals, a lower threshold for migraines and tension-type headaches.

3.4.2. Oxidative Stress in Neural Tissues

The methanol component of aspartame (10%) is metabolized into formaldehyde, a known neurotoxin. Research suggests that chronic exposure to these metabolites can induce mitochondrial dysfunction in neurons and glial cells. By increasing the production of reactive oxygen species (ROS) and decreasing the activity of antioxidant enzymes like superoxide dismutase (SOD) and catalase (CAT), aspartame may contribute to a state

of chronic, low-grade neuroinflammation (Jones et al., 2023). This mechanism is increasingly being studied in the context of neurodegenerative processes, although longitudinal human data remain inconclusive.

3.4.3. Aspartic Acid as a Chronic Excitotoxin

While much focus is placed on phenylalanine and methanol, the role of aspartic acid (40% of the molecule) as a neuro-excitatory agent is often overlooked in consumer safety assessments. Aspartic acid is an agonist of the *N*-methyl-D-aspartate (NMDA) receptors in the central nervous system.

Under normal physiological conditions, aspartate and glutamate serve as vital excitatory neurotransmitters. However, sustained, high-level exposure - as seen in individuals consuming multiple low-calorie beverages daily - can lead to excitotoxicity. This process involves excessive activation of NMDA receptors, leading to an uncontrolled influx of calcium ions into the neuron. The surge in intracellular calcium disrupts the mitochondrial membrane potential, leading to the release of cytochrome c and the initiation of the apoptotic cascade (Czarnecka et al., 2021; Prantera et al., 2023).

This slow excitotoxicity may not manifest as acute neurological symptoms but could contribute to chronic conditions. Studies have suggested that chronic aspartame intake can alter the density of NMDA receptors in the hypothalamus and hippocampus, areas of the brain critical for appetite regulation and memory. This provides a neurological basis for the behavioral alterations - such as increased anxiety and cognitive blunting - reported by long-term consumers in recent clinical reviews (Jones et al., 2023).

4. Socio-Regulatory Challenges and Risk Communication

The aspartame controversy is as much a sociological phenomenon as it is a toxicological one. The divergence in safety assessments between international health organizations has created a landscape of institutional distrust among consumers (More et al., 2024).

4.1. The IARC vs. JECFA Divergence: Hazard vs. Risk

The 2023 dual release of findings by the IARC and JECFA serves as a case study in complex risk communication. As a hazard identification body, the IARC's Group 2B classification signals that aspartame has the potential to cause cancer under certain conditions, based on *limited evidence* (Riboli et al., 2023). Conversely, JECFA performs a risk assessment, determining the actual likelihood of harm under normal consumption patterns. Their conclusion that the ADI of 40 mg/kg remains safe was intended to provide clinical reassurance (Landrigan & Belpoggi, 2023).

However, from a public health perspective, these nuanced distinctions are often lost. As highlighted in recent literature (El Doueihy et al., 2025), the media portrayal of a substance as possibly carcinogenic often overrides the technical reassurance of the ADI, leading to a phenomenon known as risk amplification. This results in significant shifts in market trends, where consumers migrate toward aspartame-free products that may contain newer, even less-studied synthetic sweeteners.

4.2. Socio-Economic Implications and Health Equity

The impact of chronic metabolic conditions on productivity and public health is profound. Aspartame consumption is often higher in lower-income populations, where low-calorie beverages and processed sugar-free foods serve as accessible alternatives to high-calorie diets. If aspartame indeed contributes to gut dysbiosis and insulin resistance (Aronica et al., 2024; Suez et al., 2022), the long-term socioeconomic burden of treating these metabolic complications could outweigh the short-term benefits of caloric reduction. This creates a health equity gap, where the most vulnerable populations are exposed to the highest cumulative levels of poorly understood synthetic additives (Landrigan & Belpoggi, 2023).

5. Comparative Synthesis of Evidence: Reconciling Divergent Scientific Outcomes

The scientific literature regarding aspartame is characterized by a significant heterogeneity of results, which often leads to confusion in both clinical practice and public health policy. To provide a robust framework for understanding these discrepancies, it is necessary to move beyond a simple list of findings and instead perform a comparative synthesis that accounts for study design, exposure duration, and the funding effect.

5.1. Observational Cohorts vs. Controlled Clinical Trials

A primary source of divergence in aspartame research is the methodological gap between large-scale epidemiological studies and short-term randomized controlled trials (RCTs). As exemplified by the NutriNet-Santé cohort (Debras et al., 2022), observational studies tend to identify long-term correlations between high

aspartame intake and chronic conditions such as breast cancer and metabolic syndrome. Critics often argue that these studies are prone to residual confounding.

However, as discussed by Landrigan and Belpoggi (2023), short-term RCTs - which often show aspartame to be metabolically neutral - are frequently too brief (typically 4 to 12 weeks) to capture the slow, cumulative processes of epigenetic modification or mitochondrial DNA damage. The synthesis of evidence suggests that while aspartame may not cause acute metabolic spikes, its chronic, low-dose impact on the gut microbiome and oxidative stress levels (as measured by 8-OHdG biomarkers) requires a longitudinal perspective that RCTs simply cannot provide.

5.2. The Impact of Exposure Windows: Prenatal vs. Adult Data

Another layer of complexity in the evidence base is the window of exposure. Many studies that failed to find carcinogenic effects in rodents utilized adult models. In contrast, the Ramazzini Institute studies (Soffritti et al., 2010) utilized a life-span model, including prenatal exposure.

This distinction is crucial from a public health perspective. The evidence synthesis reveals that when aspartame is introduced during fetal development or early childhood, the risk of developing lymphomas, leukemias, and hepatocellular carcinoma in later life appears significantly higher. This suggests that the dose-response relationship is not linear but is heavily dependent on the developmental stage of the organism - a concept known as metabolic programming. By synthesizing these findings, this review concludes that safety thresholds designed for healthy adults may be fundamentally inadequate for protecting pregnant women and pediatric populations (Aronica et al., 2024; Payen de la Garanderie et al., 2025)

5.3. Conflict of Interest and the Funding Bias in Safety Assessments

A rigorous synthesis of the aspartame controversy must also address the socio-economic dimension of scientific production. Systematic reviews of the literature have identified a stark contrast between industry-funded and independently funded research.

Independent studies, predominantly those published in the last five years (2021–2026), increasingly highlight the disruption of the incretin-gut axis and the potential for genotoxicity (Prantera et al., 2023). Conversely, industry-funded dossiers - which form a large part of the evidence base for regulatory bodies like the JECFA - consistently report no adverse effects. This divergence creates a meta-controversy regarding the objectivity of food safety science. The current consensus among independent researchers is that the absence of acute toxicity should not be mistaken for proof of long-term safety, especially in the context of the IARC (2023) classification, which prioritized independent, peer-reviewed data over unpublished industry reports (More et al., 2024; Riboli et al., 2023).

5.4. Integrating Molecular Mechanisms with Epidemiological Observations

The final pillar of this synthesis is the mechanistic bridge. The epidemiological findings of increased cancer risk in the NutriNet-Santé study are no longer isolated observations; they are supported by the molecular evidence of formaldehyde-DNA cross-linking and glutathione depletion (Czarnecka et al., 2021).

When these two fields are synthesized, a coherent narrative emerges: aspartame acts as a chronic, low-level oxidative stressor. While the body can neutralize occasional exposure, the ubiquity of aspartame in modern processed diets leads to a steady state of reactive metabolites that eventually overwhelms cellular repair mechanisms. This integrative view provides a much stronger foundation for public health warnings than the previous, fragmented approach to sweetener safety.

6. Vulnerable Populations and the Paradigm of Metabolic Programming

The aspartame dilemma is most acute when examining its impact on vulnerable populations, specifically pregnant women and children. Historically, regulatory safety thresholds like the acceptable daily intake (ADI) were designed based on adult physiological models. However, emerging research in metabolic programming suggests that early-life exposure to non-nutritive sweeteners (NNS) may have long-term health consequences that are not captured by traditional toxicological metrics (Landrigan & Belpoggi, 2023).

6.1. Prenatal Exposure and Fetal Development

Pregnancy represents a critical window of biological vulnerability. While aspartame metabolites - aspartic acid and phenylalanine - are naturally occurring amino acids, their concentrated delivery via synthetic additives may alter the intrauterine environment. Research by Payen de la Garanderie et al. (2025**)** suggests that maternal consumption of aspartame can lead to the transplacental transfer of its breakdown products. Of particular concern is methanol, which is metabolized into formaldehyde. Although the levels generated from a single serving are low, the fetus lacks the fully developed enzymatic machinery, such as alcohol dehydrogenase, to detoxify these compounds efficiently. This cumulative exposure, even at sub-toxic levels, has been hypothesized to induce subtle epigenetic modifications in fetal tissues, potentially increasing the risk of metabolic syndrome and obesity later in life (Aronica et al., 2024).

6.2. Early Childhood Consumption and the Sweetness Threshold

In pediatric populations, the widespread use of aspartame in sugar-free juices, yogurts, and snacks has introduced a new public health challenge. From a behavioral perspective, early exposure to high-intensity sweeteners like aspartame can skew a child's flavor preference profile. Aspartame is significantly sweeter than sucrose, and its regular consumption can lead to a blunting of taste receptors, making natural sugars found in fruits seem less appealing. This sensory maladaptation often drives a cycle of craving for ultra-processed, highly palatable foods (Suez et al., 2022). Furthermore, large-scale observational data, including updates from the NutriNet-Santé cohort, have noted a paradoxical correlation regarding adiposity and body mass index (BMI): children who consume higher amounts of NNS-sweetened products often exhibit higher rates of weight gain. As analyzed by Riboli et al. (2023), this may be due to the compensation effect, where the lack of calories in a sweet beverage leads to overconsumption of calories in subsequent meals.

6.3. Long-Term Epigenetic Implications

The concept of the developmental origins of health and disease (DOHaD) is central to the modern critique of aspartame. Evidence from recent studies suggests that NNS exposure during infancy may alter the initial colonization of the gut microbiome. Since the early microbiome plays a foundational role in training the infant's immune system and metabolic pathways, aspartame-induced dysbiosis during this period could predispose individuals to chronic inflammatory conditions (Aronica et al., 2024; Suez et al., 2022).

7. The Diet Halo Effect and Consumer Psychology

From a psychological and public health perspective, the widespread acceptance of aspartame is deeply rooted in the diet halo effect. This cognitive bias occurs when consumers perceive a product as inherently healthier simply because it bears a zero-sugar or light label, often leading them to overlook other nutritional deficiencies or to overconsume other energy-dense foods.

7.1. Risk Perception and Labeling Technology

The IARC Group 2B classification has significantly disrupted this halo effect. As discussed by (El Doueihy et al., 2025), the proliferation of possibly carcinogenic warnings - even if primarily in media discourse rather than on official product labels - creates a state of cognitive dissonance for consumers. Individuals are forced to navigate a complex choice between the well-established cardiometabolic risks of refined sugars and the uncertain, emerging risks of synthetic sweeteners.

The food industry is responding to this shift in consumer risk perception by moving toward clean label formulations. However, this often involves replacing aspartame with newer, less-studied alternatives, such as monk fruit extract or allulose. This dynamic creates a regulatory treadmill, where public health policy constantly struggles to keep pace with rapid technological shifts in food chemistry (Landrigan & Belpoggi, 2023).

7.2. Socio-Economic Stratification of Consumption

Epidemiological data suggest that NNS consumption is not evenly distributed across socio-economic demographics. Higher consumption rates are frequently observed in populations with limited access to fresh, whole foods. This uneven distribution frames the aspartame debate as a critical issue of health equity: if these synthetic sweeteners contribute to metabolic dysfunction, their ubiquity in low-cost, ultra-processed foods may actively exacerbate existing health disparities (More et al., 2024).

8. Global Regulatory Divergence: A Comparative Policy Analysis

The aspartame controversy serves as a quintessential example of how the same scientific data can be interpreted differently across various regulatory jurisdictions. This divergence is not merely a matter of toxicological debate but is rooted in differing legal philosophies regarding public health and consumer safety (More et al., 2024; Panidi et al., 2025).

8.1. The Precautionary Principle vs. Risk-Benefit Analysis

In the European Union, the European Food Safety Authority (EFSA) often operates under the precautionary principle, which allows for regulatory intervention if there is scientific uncertainty about a potential risk, even if that risk is not yet fully proven. In contrast, the United States Food and Drug Administration (FDA) typically adheres to a substantial evidence model, requiring robust proof of harm before altering long-standing safety approvals (Landrigan & Belpoggi, 2023).

The 2023 IARC classification has intensified this rift. While the FDA formally disagreed with the IARC's findings, citing flaws in the methodology of the underlying animal studies, several European nations have used the IARC report as a catalyst to expand sugar-sweetened beverage (SSB) taxes to include non-nutritive sweeteners. As highlighted by (Rathaus et al., 2024), these policy shifts represent a move toward preventative nutrition, where the goal is to reduce the overall sweetness intensity of the human diet rather than merely substituting one chemical for another.

8.2. Institutional Trust and the Role of Industry-Funded Research

A significant factor in the socio-regulatory discourse is the source of research funding. Narrative reviews of the literature have noted that studies funded by the food and beverage industry are statistically more likely to report neutral or beneficial effects of aspartame, whereas independently funded studies, such as the NutriNet-Santé cohort, are more likely to identify potential health risks (Debras et al., 2022).

This funding bias has a corrosive effect on institutional trust. When regulatory bodies like the JECFA rely heavily on industry-submitted dossiers for their risk assessments, it creates a perception of bias in the public sphere. Modern public health policy in 2026 is increasingly calling for open science mandates, where all raw data from safety trials must be accessible for independent third-party verification to restore consumer confidence (Rathaus et al. 2024; More et al., 2024)

9. Discussion

The synthesis of evidence presented in this review reveals a significant disconnect between historical regulatory consensus and emerging molecular data. While JECFA maintains that the current acceptable daily intake (ADI) of 40 mg/kg is protective, our analysis of recent literature (2021–2026) suggests that this threshold may not account for subtle, long-term perturbations in cellular redox balance and metabolic signaling (Landrigan & Belpoggi, 2023).

9.1. The Oxidative Stress Signature: A Biomarker Perspective

One of the most compelling arguments for a re-evaluation of aspartame's safety lies in the quantifiable increase in oxidative stress biomarkers. Unlike previous decades where safety was measured primarily through gross pathological changes in animal models, modern toxicology focuses on sub-clinical molecular lesions.

As detailed in mechanistic studies (Czarnecka et al., 2021; Prantera et al., 2023), chronic aspartame consumption is associated with a significant rise in 8-hydroxy-2'-deoxyguanosine, a critical biomarker of oxidative DNA damage. Furthermore, the elevation of malondialdehyde (MDA) - a marker of lipid peroxidation - indicates that oxidative damage extends to the polyunsaturated fatty acids of cellular and mitochondrial membranes. In clinical cohorts, individuals with high non-nutritive sweetener (NNS) intake exhibit a diminished glutathione (GSH) to glutathione disulfide (GSSG) ratio. This systemic antioxidant depletion suggests that even at doses below the ADI, aspartame may prime the cellular environment for chronic inflammation and genomic instability, providing a plausible biological bridge to the hepatocellular carcinoma observations reported by the IARC (2023).

9.2. Addressing Reverse Causality and Sick Quitter Confounders

A recurring critique in epidemiological literature is that the observed link between aspartame and metabolic disease is a result of reverse causality - that individuals who are already overweight or diabetic are simply more likely to consume low-calorie products. However, the robustness of the NutriNet-Santé cohort challenges this assumption (Debras et al., 2022).

By employing time-dependent Cox proportional hazard models and adjusting for a comprehensive array of confounders, researchers demonstrated that the risk remains statistically significant. Moreover, the biological plausibility provided by recent microbiome studies shifts the burden of proof (Suez et al., 2022). This is no longer a simple correlation; it is the identification of a mechanism whereby NNS-induced dysbiosis alters the host's glucose tolerance, effectively turning a sugar-free intervention into a metabolic disruptor.

9.3. The Gut-Liver-Brain Axis: A Systems Biology Approach

The discussion must move beyond a single-organ view of toxicity. Aspartame's systemic impact is primarily mediated through the gut-liver-brain axis. In the gut, aspartame alters intestinal epithelial barrier integrity, triggering the release of pro-inflammatory cytokines, such as TNF-α and IL-6 (Aronica et al., 2024). In the liver, these cytokines, alongside formaldehyde-derived reactive species, promote hepatic stellate cell activation, a precursor to non-alcoholic fatty liver disease (NAFLD). Simultaneously in the brain, the disruption of the large neutral amino acid (LNAA) transport system at the blood-brain barrier alters the synthesis of serotonin and dopamine (Prantera et al., 2023).

This interconnected cascade explains why chronic aspartame exposure manifests in diverse symptoms, ranging from insulin resistance to neuropsychiatric alterations like anxiety and cognitive blunting. By treating aspartame merely as an inert calorie-cutter, public health policy has overlooked its role as a systemic physiological disruptor.

9.4. Socio-Regulatory Inertia and the Evidence Gap

The divergence between the IARC's hazard identification and the FDA or EFSA's risk assessment represents more than a scientific disagreement; it manifests socio-regulatory inertia. Regulatory bodies often rely on outdated good laboratory practice (GLP) studies conducted by industry-funded entities. In contrast, the IARC classification prioritized independent, peer-reviewed academic research utilizing sensitive molecular techniques (Landrigan & Belpoggi, 2023; Riboli et al., 2023).

This evidence gap creates a paradox in health equity. Vulnerable populations - particularly children, pregnant women, and lower-income demographics - are often the highest consumers of NNS-sweetened products. Relying on outdated regulatory models that ignore epigenetic programming and microbiome shifts subjects these groups to a prolonged, uncontrolled nutritional experiment (More et al., 2024).

9.5. Limitations and Future Directions

Despite the depth of current research, several limitations persist, most notably the short duration of most clinical trials. To address the long-term oncological and metabolic effects of aspartame, future research must prioritize multi-omic studies that correlate microbiome shifts with serum metabolomics and epigenetic markers in NNS consumers. Additionally, there is a critical need for refined exposure metrics that account for the cumulative cocktail effects of multiple NNS (e.g., aspartame, acesulfame-K, and sucralose). From a policy perspective, implementing precautionary labeling could effectively inform consumers of the metabolic and oncological uncertainties recently identified by the IARC (2023).

10. Conclusions

This narrative review confirms that the safety of aspartame is no longer a settled question. The convergence of epidemiological data from the NutriNet-Santé cohort, molecular toxicology highlighting 8-OHdG and DNA-protein crosslink (DPC) formation, and metabolic science detailing gut-insulin axis disruption suggests that the current acceptable daily intake (ADI) may be insufficient to prevent chronic, subclinical health perturbations.

As public health advances toward more personalized and technologically driven paradigms, the aspartame dilemma serves as a critical lesson in the limits of synthetic reductionism. Reducing caloric intake by introducing reactive chemical metabolites is a strategy that may have reached its biological and social shelf life. Moving forward, public health initiatives must prioritize overall sweetness reduction and metabolic resilience over the technological substitution of sugar, ensuring that the pursuit of weight management does not come at the expense of long-term genomic and systemic integrity.

REFERENCES

1. Aronica, L., Canalias-Reuter, L., & Suez, J. (2024). Artificial sweeteners: A double-edged sword for gut microbiome and metabolic health. *Nutrients, 16*(8), 1120. https://doi.org/10.3390/nu16081120
2. Czarnecka, K., Pilarz, P., Rogut, A., Maj, P., Szymańska, J., Olejnik, Ł., & Szymański, P. (2021). Aspartame—True or false? Narrative review of safety analysis. *Nutrients, 13*(6), 1957. https://doi.org/10.3390/nu13061957
3. Debras, C., Chazelas, E., Srour, B., Druesne-Pecollo, N., Esseddik, Y., Szabo de Edelenyi, F., Agaësse, C., De Sa, A., Lutchia, R., Gigandet, S., Huybrechts, I., Julia, C., Kesse-Guyot, E., Lévy, R., Touvier, M., & Deschasaux-Tanguy, M. (2022). Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort study. *PLoS Medicine, 19*(3), e1003950. https://doi.org/10.1371/journal.pmed.1003950
4. International Agency for Research on Cancer. (2023). *IARC monographs on the identification of carcinogenic hazards to humans: Aspartame*. World Health Organization. https://www.iarc.who.int/news-events/aspartame-hazard-and-risk-assessment-results-released/
5. Jones, A. M., Smith, K. L., & Davis, R. J. (2023). Neurobehavioral effects of phenylalanine and aspartic acid: A longitudinal analysis. *Journal of Neurochemistry, 165*(4), 512–528. https://doi.org/10.1111/jnc.15820
6. Landrigan, P. J., & Belpoggi, F. (2023). The IARC assessment of the carcinogenicity of aspartame. *The Lancet Oncology, 24*(8), 848–850. https://doi.org/10.1016/S1470-2045(23)00341-8
7. More, S., Simon, S. N., & Steenkamp, J. (2024). Risk communication and institutional trust: The socio-regulatory challenges of food additives. *Journal of Public Health Policy, 45*(1), 12–29. https://doi.org/10.1057/s41271-023-00456-w
8. Prantera, M., Rossi, M., & Gallo, A. (2024). Oxidative stress and DNA damage induced by low-dose methanol: A re-evaluation of aspartame safety. *Toxicology Reports, 12*, 145–158. https://doi.org/10.1016/j.toxrep.2024.01.005
9. Riboli, E., Beland, F. A., Lachenmeier, D. W., Marques, M. M., Phillips, D. H., Schernhammer, E., & Schubauer-Berigan, M. K. (2023). Carcinogenicity of aspartame, methyleugenol, and isoeugenol. *The Lancet Oncology, 24*(8), 832–834. https://doi.org/10.1016/S1470-2045(23)00341-8
10. Soeller, W. (2010). Chronic methanol exposure and formaldehyde adducts: Implications for genomic stability. *Toxicologic Pathology, 38*(3), 421–435. https://doi.org/10.1177/0192623310363813
11. Soffritti, M., & Padovani, M. (2023). Re-evaluating the Ramazzini Institute studies on aspartame in the context of IARC Group 2B classification. *Environmental Health, 22*(1), 45. https://doi.org/10.1186/s12940-023-00995-1
12. Soffritti, M., Belpoggi, F., Manservigi, M., Tibaldi, E., Lauriola, M., Falcioni, L., & Bua, L. (2010). Aspartame administered in feed, beginning prenatally through life span, induces cancers of the liver and lung in male mice. *American Journal of Industrial Medicine, 53*(12), 1197–1206. https://doi.org/10.1002/ajim.20896
13. Suez, J., Cohen, Y., Valdés-Mas, R., Mor, U., Dori-Bachash, M., Federici, S., Zmora, N., Leshem, A., Heinemann, M., Linevsky, R., Zur, M., Ben-Zeev, B., Fruchtman, A., Pevsner-Fischer, M., Banias, O., Itav, S., Harmelin, A., Schwartz, S., Sirota-Madi, A., ... Elinav, E. (2022). Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance. *Cell, 185*(18), 3307–3328.e19. https://doi.org/10.1016/j.cell.2022.07.016
14. U.S. Food and Drug Administration. (2024). *Aspartame and other sweeteners in food: Regulatory status and safety*. https://www.fda.gov/food/food-additives-petitions/aspartame-and-other-sweeteners-food
15. World Health Organization. (2023). *Use of non-sugar sweeteners: WHO guideline*. https://www.who.int/publications/i/item/9789240073616